Novel Macrocyclic 1,3,4-Oxadiazoles as CFTR Modulators for Treating Cystic Fibrosis.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 West Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2022 Jun 30;13(7):1014-1015. doi: 10.1021/acsmedchemlett.2c00288. eCollection 2022 Jul 14.
Abstract
摘要
相似文献
1
Novel Macrocyclic 1,3,4-Oxadiazoles as CFTR Modulators for Treating Cystic Fibrosis.新型大环1,3,4-恶二唑作为治疗囊性纤维化的CFTR调节剂
ACS Med Chem Lett. 2022 Jun 30;13(7):1014-1015. doi: 10.1021/acsmedchemlett.2c00288. eCollection 2022 Jul 14.
2
[Therapeutic update in cystic fibrosis].[囊性纤维化的治疗进展]
Rev Med Interne. 2014 Jun;35(6):388-92. doi: 10.1016/j.revmed.2013.11.003. Epub 2013 Dec 3.
3
Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.囊性纤维化跨膜电导调节因子修饰药物：囊性纤维化治疗的未来。
Ann Pharmacother. 2012 Jul-Aug;46(7-8):1065-75. doi: 10.1345/aph.1R076. Epub 2012 Jun 26.
4
Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis.接受囊性纤维化跨膜传导调节因子调节剂治疗的囊性纤维化患者肝硬化发病率降低。
World J Hepatol. 2022 Feb 27;14(2):411-419. doi: 10.4254/wjh.v14.i2.411.
5
Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.治疗囊性纤维化跨膜电导调节因子缺陷型囊性纤维化患者。
Semin Respir Crit Care Med. 2019 Dec;40(6):762-774. doi: 10.1055/s-0039-1696664. Epub 2019 Oct 28.
6
Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis.囊性纤维化中单一和联合 CFTR 调节剂与细菌感染的相互作用。
Microbiol Spectr. 2023 Feb 14;11(1):e0408322. doi: 10.1128/spectrum.04083-22. Epub 2023 Jan 10.
7
Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators.不适合当前 CFTR 调节剂的囊性纤维化患者的治疗方法。
Cells. 2021 Oct 19;10(10):2793. doi: 10.3390/cells10102793.
8
Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.囊性纤维化：一种用于囊性纤维化跨膜传导调节因子调控治疗的新型药理学方法。
J Am Osteopath Assoc. 2015 Sep;115(9):546-55. doi: 10.7556/jaoa.2015.112.
9
Pulmonology: CFTR modulators for cystic fibrosis.肺病学：用于囊性纤维化的CFTR调节剂
JAAPA. 2013 Feb;26(2):59-60. doi: 10.1097/01720610-201302000-00013.
10
Review of CFTR modulators 2020.2020 年 CFTR 调节剂的回顾。
Pediatr Pulmonol. 2021 Dec;56(12):3595-3606. doi: 10.1002/ppul.25627. Epub 2021 Aug 18.
本文引用的文献
1
Exercise intolerance in cystic fibrosis-the role of CFTR modulator therapies.囊性纤维化运动不耐受——CFTR 调节剂治疗的作用。
J Cyst Fibros. 2022 Mar;21(2):282-292. doi: 10.1016/j.jcf.2021.11.011. Epub 2021 Dec 24.
2
Small-molecule drugs for cystic fibrosis: Where are we now?用于治疗囊性纤维化的小分子药物：我们目前处于什么阶段？
Pulm Pharmacol Ther. 2022 Feb;72:102098. doi: 10.1016/j.pupt.2021.102098. Epub 2021 Nov 15.
3
Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies.囊性纤维化相关性肝病：CFTR 调节剂治疗时代的临床特征、诊断和监测方法。
J Hepatol. 2022 Feb;76(2):420-434. doi: 10.1016/j.jhep.2021.09.042. Epub 2021 Oct 20.
4
Cancer in Cystic Fibrosis: A Narrative Review of Prevalence, Risk Factors, Screening, and Treatment Challenges: Adult Cystic Fibrosis Series.囊性纤维化相关癌症：患病率、风险因素、筛查和治疗挑战的叙述性综述：成人囊性纤维化系列。
Chest. 2022 Feb;161(2):356-364. doi: 10.1016/j.chest.2021.09.003. Epub 2021 Sep 15.
5
Cardiovascular complications in cystic fibrosis: A review of the literature.囊性纤维化中的心血管并发症：文献综述。
J Cyst Fibros. 2022 Jan;21(1):18-25. doi: 10.1016/j.jcf.2021.04.016. Epub 2021 Jun 14.
6
Cystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation.囊性纤维化年度回顾 2020：第 2 部分 肺部疾病、感染和炎症。
Pediatr Pulmonol. 2022 Feb;57(2):347-360. doi: 10.1002/ppul.25459. Epub 2021 May 25.
Zotero 插件